LAURUS
GenericsLAURUS is a generic drug manufacturer focused on Infectious Disease, Respiratory, Cardiovascular. Key products include EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE.
LAURUS's Key Drugs
LAURUS's core commercial portfolio centers on SACUBITRIL AND VALSARTAN, EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE, LOPINAVIR AND RITONAVIR, spanning Infectious Disease and Respiratory — its most strategically important drugs approved in the last 15 years.
Heart Failure
Human Immunodeficiency Virus
HIV Infection
HIV-1 infection
LAURUS's Recent FDA Approvals
New NDA/BLA approvals for LAURUS over the last two years — novel drugs only, excluding generics and label supplements.
LAURUS's Therapeutic Areas
LAURUS's approved drugs and pipeline span 4 therapeutic areas, led by Infectious Disease and Respiratory, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
LAURUS's Top Competitors
LAURUS's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and LEDERLE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
LAURUS Pipeline Snapshot
Active clinical trials for LAURUS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SACUBITRIL AND VALSARTAN leads revenue
- • 4 key drugs tracked
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (3)
Discontinued (3)
Company Info
- First Approval
- 2018-08-27
- Latest
- 2026-07-10
- Applications
- 34